Ulcerative colitis

An FDA approval means TREMFYA is now an additional, officially authorized treatment option for adults with moderately to severely active Crohn's disease. The drug offers both IV and SC induction choices and established...

The paper links a Crohn’s disease GWAS signal to reduced LACC1 expression in lymphocytes and to altered immunometabolic function, clarifying a potential mechanism by which genetic variation contributes to IBD risk. It...

This highlights a local family’s experience with pediatric Crohn’s disease, showing how community support and Foundation programs can help patients and caregivers connect, fundraise, and access resources.

Spanish-speaking people with Crohn’s disease or ulcerative colitis often lack culturally tailored, medically reviewed resources. A Spanish-language community can improve access to information, peer support, and...

Cure8 could only read part of this source from ajmc.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Ulcerative colitis and Diet and lifestyle.

Dietary patterns may differ between people who develop Crohn’s disease or ulcerative colitis and their healthy relatives; understanding these associations could help guide prevention research and personalized nutrition...

Spanish-speaking people with Crohn’s disease or ulcerative colitis often face language and access barriers to care and information. A dedicated Spanish-language community can improve access to medically reviewed...

Take Steps is a community fundraising walk that raises money for IBD research, patient support, and awareness. Participating or supporting the event can connect people with local IBD resources and others who understand...

This project aims to develop wearable-based digital biomarkers to detect IBD flares earlier and make remote monitoring easier, which could help patients and clinicians manage disease more proactively. It describes...

Local support and education events help people with IBD connect with specialists and peers, learn about treatments and lifestyle tips, and access mental-health and pediatric/caregiver resources.

Cure8 found this source from academic.oup.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Ulcerative colitis, and Diet and lifestyle. Open the original article for the full details.

People with IBD (Crohn’s disease or UC) have a higher risk of blood clots, especially during active disease. Long flights increase clot risk because of prolonged immobility, so the article’s travel-focused precautions...

If metabolomic blood markers can reliably indicate IBD risk years before symptoms, researchers may better understand disease development and eventually design earlier detection or prevention strategies. For patients, the...

These are phase 3 results showing subcutaneous guselkumab helped more people reach clinical and endoscopic goals than placebo in moderate-to-severe UC and Crohn’s disease; a fully subcutaneous option could offer more...

The study suggests anxiety, depression, poor sleep, and low exercise are linked with higher risk of IBD flares. That means mental health and lifestyle may be important parts of managing IBD alongside medical care.

This meta-analysis suggests people with IBD—especially those with Crohn’s disease—have a modestly increased risk of stroke. That makes cardiovascular risk assessment and prevention potentially more important for people...

This study suggests machine learning of stool microbiome data could eventually help distinguish IBD (especially Crohn’s) from healthy people and some other bowel or systemic conditions.

A CE mark under the EU IVDR means a new non-invasive test aimed at identifying dietary triggers for people with UC or Crohn’s may become available in Europe. Tests like this could affect how some patients and clinicians...

A new CE-marked food-intolerance diagnostic could give people with Crohn’s or UC a non-invasive tool to explore dietary triggers alongside clinical care. Regulatory certification means the products met EU safety and...

Cure8 could only read part of this source from appliedclinicaltrialsonline.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Ulcerative colitis, Crohn's disease, and Inflammatory...

Based on the title and source metadata, this appears to be a patient story related to Ulcerative colitis, Inflammatory bowel disease, and Community and awareness. The original article is from townsvillebulletin.com.au.

Detecting neoplasia early is a central goal of IBD surveillance; this study suggests virtual chromoendoscopy may find more lesions than dye or white light in real-world practice, which could influence how surveillance is...

A new FDA‑approved biosimilar to ustekinumab is now available in the U.S., which may increase treatment options and lower out‑of‑pocket costs for people with Crohn’s disease or ulcerative colitis. The article highlights...

A new FDA‑approved ustekinumab biosimilar (YESINTEK) is now available in the US for Crohn’s disease and ulcerative colitis, which may increase treatment options and lower costs. Coverage and copay support at launch could...

The Phase 2b results suggest the investigational TL1A drug duvakitug improved clinical and endoscopic outcomes versus placebo in both ulcerative colitis and Crohn’s disease, which could expand future treatment options if...

Older adults with IBD have higher cardiovascular risk; medication choice may affect cardiovascular outcomes. This study suggests ustekinumab users had fewer deaths and some cardiac events than vedolizumab users, which...

Cure8 could only read part of this source from devdiscourse.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Ulcerative colitis, and Ustekinumab.

The article reports new phase 2 trial data for duvakitug, an experimental anti‑TL1A treatment for ulcerative colitis and Crohn’s disease, which helps compare it to rival candidates and shapes upcoming phase 3 plans.

This reports Phase 2b trial results for duvakitug showing improved remission and endoscopic response versus placebo in UC and CD—early evidence that could lead to a new treatment option if later trials confirm benefit...

Cure8 could only read part of this source from money.rediff.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Ulcerative colitis, and Ustekinumab.

The study explores whether larger spleen size might play a causal role in the risk of ulcerative colitis or Crohn’s disease, using genetic data to reduce confounding. If a causal link exists, spleen volume could be a...

If approved, Tremfya SC induction could provide a fully subcutaneous induction and maintenance option for people with moderately to severely active ulcerative colitis, which may be more convenient than IV induction.

New Phase 2b data were presented for duvakitug, an investigational antibody for UC and Crohn’s disease; people with IBD may see this as a potential future treatment option if later trials are positive. The report focuses...

This press release reports phase 2 evidence that a new experimental antibody (duvakitug) showed clinical, endoscopic, and histologic improvements in both UC and Crohn’s disease, which could lead to a new treatment option...

A new antibody, duvakitug, showed higher remission/response rates than placebo in Phase 2b study data for both ulcerative colitis and Crohn’s disease, which could lead to a new treatment option if Phase 3 trials confirm...

Patients and clinicians following new, non‑immunosuppressive approaches to UC may be interested because MB310 is an oral live‑biotherapeutic designed to induce remission and is entering clinical testing.

A new ustekinumab biosimilar (SELARSDI) is now available in the U.S. for Crohn’s disease and ulcerative colitis, which may expand treatment options and affect access or cost for patients on biologic therapy.

Local fundraising events raise money and visibility for people living with Crohn’s and colitis and can connect patients, families, and supporters. Participating or volunteering supports the charity and can offer social...

This is early-stage research about combining antibody targets (α4β7 and TL1A) for IBD; if validated in humans, combination biologics could offer improved effectiveness or dosing convenience.

This announcement signals growing clinical and preclinical data for obefazimod, an investigational IBD drug; it includes a preclinical report on anti-fibrotic activity, a complication important in Crohn’s disease.

A validated AI biomarker that predicts which IBD treatments are likely to work could reduce trial-and-error in treatment choices, potentially shortening time to effective therapy for people with Crohn's disease or...

Cure8 indexed this Crohn's and IBD-related source from healio.com. It is tagged for Inflammatory bowel disease, Crohn's disease, and Ulcerative colitis. Open the original article for the full details.

Longer-term (two-year) results suggest mirikizumab (Omvoh) can maintain clinical and endoscopic benefits for many people with Crohn’s disease, including some with prior biologic failure, which is important when weighing...

People with IBD who need advanced therapies may worry about cardiovascular risks linked to some JAK inhibitors. This study suggests, in a real-world cohort with cardiovascular risk factors, short-term (1-year) MACE risk...

These are multi‑year clinical results for a newly approved IL‑23p19 inhibitor (mirikizumab) showing sustained clinical and endoscopic benefit for many patients with moderate‑to‑severe Crohn’s disease, including some who...

Long-term data matter because they show whether benefits and safety of a new biologic hold up beyond the initial trial period. For people with Crohn’s disease, sustained clinical remission and endoscopic healing are...

Durable treatment responses matter to people with Crohn’s disease because sustained clinical remission and endoscopic improvement can mean fewer symptoms and less inflammation over time. Longer safety and durability data...

This article reports two-year data showing that mirikizumab (Omvoh) maintained clinical and endoscopic benefit for many people with moderate–severe Crohn’s disease, and that results across Phase 3 programs also support...